Lp(a) Tied to Higher CVD Events; Risk Reduction With IPE
New analysis of the REDUCE-IT trial suggested benefit of icosapent ethyl doesn't vary by Lp(a) level and confirmed risk for Lp(a) with high triglycerides but not cholesterol.
Source: medscape.com